Insulin structure and function.
暂无分享,去创建一个
[1] James Miller,et al. Bioavailability of Leuprolide Acetate Following Nasal and Inhalation Delivery to Rats and Healthy Humans , 1992, Pharmaceutical Research.
[2] P. Katsoyannis,et al. The importance of the B10 amino acid residue to the biological activity of insulin. [Lys10-B] human insulin , 1982 .
[3] S. Gammeltoft,et al. Receptor Binding and Tyrosine Kinase Activation by Insulin Analogues With Extreme Affinities Studied in Human Hepatoma HepG2 Cells , 1991, Diabetes.
[4] David R. Owens,et al. New horizons — alternative routes for insulin therapy , 2002, Nature Reviews Drug Discovery.
[5] G. Dixon,et al. Regeneration of Insulin Activity from the Separated and Inactive A and B Chains , 1960, Nature.
[6] S. Madsbad,et al. Intranasal insulin therapy: the clinical realities , 1995, Diabetologia.
[7] Stephen B. H. Kent,et al. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. , 2009 .
[8] K. Geisen,et al. [(A1-beta-Alanine) insulin]. , 1976, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[9] J. Olefsky,et al. Diabetes due to secretion of an abnormal insulin. , 1980, The New England journal of medicine.
[10] M. Weiss,et al. Hierarchical protein "un-design": insulin's intrachain disulfide bridge tethers a recognition alpha-helix. , 2000, Biochemistry.
[11] R. B. Merrifield,et al. The synthesis of bovine insulin by the solid phase method. , 1966, Journal of the American Chemical Society.
[12] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[13] L. Schäffer,et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.
[14] P. Katsoyannis,et al. Analogs of insulin. 1. Synthesis of destripeptide B 28-30 bovine insulin and destripeptide B 28-30 porcine (human) insulin. , 1971, Biochemistry.
[15] G. S. Gordon,et al. Nasal absorption of insulin: enhancement by hydrophobic bile salts. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Becker,et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[17] V. Vigneaud. Trail of Sulfur Research: from Insulin to Oxytocin , 1956 .
[18] T L Blundell,et al. The structure of 2Zn pig insulin crystals at 1.5 A resolution. , 1988, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[19] J. M. Beals,et al. Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. , 1995, Structure.
[20] Sylvie E. Blondelle,et al. Understanding Biology Using Peptides , 2006 .
[21] D. Brems,et al. Improved insulin stability through amino acid substitution. , 1992, Protein engineering.
[22] P G Katsoyannis,et al. Critical role of the A2 amino acid residue in the biological activity of insulin: [2-glycine-A]- and [2-alanine-A]insulins. , 1984, Biochemistry.
[23] L. Vignati,et al. Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment , 1997, Diabetes.
[24] L. Thim,et al. Secretion and processing of insulin precursors in yeast. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[25] W. Fischer,et al. A shortened insulin with full in vitro potency. , 1985, Biological chemistry Hoppe-Seyler.
[26] M. Bayne,et al. Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors. , 1989, The Journal of biological chemistry.
[27] J. Still. Development of oral insulin: progress and current status. , 2002 .
[28] K. Polonsky,et al. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. , 1984, The New England journal of medicine.
[29] R. Mirmira,et al. Importance of the character and configuration of residues B24, B25, and B26 in insulin-receptor interactions. , 1991, The Journal of biological chemistry.
[30] S. Shoelson,et al. Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions. , 1992, Biochemistry.
[31] P. Katsoyannis,et al. Steric requirements at position B12 for high biological activity in insulin. , 1993, Biochemistry.
[32] J. Meienhofer,et al. Notizen: Synthese der Insulinketten und ihre Kombination zu insulinaktiven Präparaten , 1963 .
[33] M. Dreyer,et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[34] R. Mirmira,et al. Role of the phenylalanine B24 side chain in directing insulin interaction with its receptor. Importance of main chain conformation. , 1989, The Journal of biological chemistry.
[35] T. Sanke,et al. Three mutant insulins in man , 1983, Nature.
[36] H. Zahn,et al. Hormone binding site of the insulin receptor: analysis using photoaffinity-mediated avidin complexing. , 1989, Biological chemistry Hoppe-Seyler.
[37] P. Katsoyannis,et al. Synthesis of an insulin analogue embodying a strongly fluorescent moiety, [19-Tryptophan-A]insulin , 1988, Journal of protein chemistry.
[38] D. Brandenburg. Insulin - structure, function, design , 2009 .
[39] J. Young,et al. Isolation and characterization of products formed by the action of trypsin on insulin. , 1961, The Journal of biological chemistry.
[40] K. Itakura,et al. Chemical synthesis of genes for human insulin. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[41] T. Blundell,et al. Receptor-binding region of insulin , 1976, Nature.
[42] W. Louis,et al. Effects of intranasal insulin in non-obese type II diabetics. , 1987, Diabetes research and clinical practice.
[43] G. Homandberg,et al. Synthesis of peptide bonds by proteinases. Addition of organic cosolvents shifts peptide bond equilibria toward synthesis. , 1978, Biochemistry.
[44] F. Regnier,et al. High-performance liquid chromatography of biopolymers. , 1983, Science.
[45] J. Pitts,et al. Structure and Function of Insulin , 1984 .
[46] P. Katsoyannis,et al. Nature of the B10 amino acid residue. Requirements for high biological activity of insulin. , 2009, International journal of peptide and protein research.
[47] J. Manson,et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. , 1985 .
[48] O. Pedersen,et al. Genetics of type 2 diabetes mellitus: status and perspectives , 2005, Diabetes, obesity & metabolism.
[49] D. Brandenburg. [Des-PheB1-insulin, a crystalline analogue of bovine insulin]. , 1969 .
[50] E. Gale. Two cheers for inhaled insulin , 2001, The Lancet.
[51] M. Weiss,et al. Crystal structure of allo-Ile(A2)-insulin, an inactive chiral analogue: implications for the mechanism of receptor binding. , 2003, Biochemistry.
[52] P. Katsoyannis,et al. Synthesis of deamino-A 1 sheep insulin. , 1972, Biochemistry.
[53] Y. Okada,et al. The chemical synthesis and biological evaluation of [1-L-alanine-A]-and [1-D-alanine-A]insulins. , 1978, The Journal of biological chemistry.
[54] J. Brange,et al. Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.
[55] L. Slieker,et al. Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor , 1997, Diabetologia.
[56] W. Cefalu,et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.
[57] C. Homko,et al. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. , 2003, Diabetes care.
[58] J. A. Hoffmann,et al. Chemical, Physical, and Biologic Properties of Biosynthetic Human Insulin , 1981, Diabetes Care.
[59] M. Karplus,et al. Two-dimensional NMR and photo-CIDNP studies of the insulin monomer: assignment of aromatic resonances with application to protein folding, structure, and dynamics. , 1989, Biochemistry.
[60] P. Brunetti,et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.
[61] H. Tager,et al. Role of the COOH-terminal B-chain domain in insulin-receptor interactions. Identification of perturbations involving the insulin mainchain. , 1987, The Journal of biological chemistry.
[62] P. Gruppuso,et al. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. , 1984, The New England journal of medicine.
[63] J. Flier,et al. Biological activity of nasally administered insulin in normal subjects. , 1990, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[64] L. Slieker,et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. , 1994, Hormone research.
[65] E. Arbit. The physiological rationale for oral insulin administration. , 2004, Diabetes technology & therapeutics.
[66] P G Katsoyannis,et al. Interaction between the A2 and A19 amino acid residues is of critical importance for high biological activity in insulin: [19-leucine-A]insulin. , 1984, Biochemistry.
[67] A. Wollmer,et al. The solution structure of a superpotent b‐chain‐shortened single‐replacement insulin analogue , 2008, Protein science : a publication of the Protein Society.
[68] M. A. Khan,et al. Polymethyacrylate based microparticulates of insulin for oral delivery: preparation and in vitro dissolution stability in the presence of enzyme inhibitors. , 2001, International journal of pharmaceutics.
[69] G. Dodson,et al. 1H nuclear magnetic resonance study of the histidine residues of insulin. , 1981, Journal of molecular biology.
[70] H. Zahn,et al. [Partial synthesis and properties of des-A1-glycine-insulin (author's transl)]. , 1975, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[71] S. Shoelson,et al. Heteronuclear 2D NMR studies of an engineered insulin monomer: assignment and characterization of the receptor-binding surface by selective 2H and 13C labeling with application to protein design. , 1991, Biochemistry.
[72] W. Cefalu. Concept, strategies, and feasibility of noninvasive insulin delivery. , 2004, Diabetes care.
[73] C. Horváth,et al. High-speed high-performance liquid chromatography of peptides and proteins. , 1995, Journal of chromatography. A.
[74] J. Conlon. Evolution of the insulin molecule: insights into structure-activity and phylogenetic relationships , 2001, Peptides.
[75] M. Kipnes,et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. , 2003, Diabetes care.
[76] R. Obermeier,et al. Der Methylsulfonyläthyloxycarbonyl-Rest als reversible Aminoschutzgruppe für Insulin , 1975 .
[77] F. Sanger,et al. The disulphide bonds of insulin. , 1955, The Biochemical journal.
[78] B. Riniker,et al. Totalsynthese von Humaninsulin. IV. Beschreibung der Endstufen , 1977 .
[79] M. Weiss,et al. Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue. , 1996, Journal of molecular biology.
[80] A. Gundlach,et al. Relaxin: new peptides, receptors and novel actions , 2003, Trends in Endocrinology & Metabolism.
[81] M Fickova,et al. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[82] M. Weiss,et al. Diabetes-associated mutations in insulin: consecutive residues in the B chain contact distinct domains of the insulin receptor. , 2004, Biochemistry.
[83] Wenhua Jia,et al. A cavity‐forming mutation in insulin induces segmental unfolding of a surrounding α‐helix , 2002 .
[84] D. Steiner,et al. Cross-linking of a B25 azidophenylalanine insulin derivative to the carboxyl-terminal region of the alpha-subunit of the insulin receptor. Identification of a new insulin-binding domain in the insulin receptor. , 1994, The Journal of biological chemistry.
[85] J. Plank,et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. , 2005, Diabetes care.
[86] Satoe H. Nakagawa,et al. Mutational analysis of invariant valine B12 in insulin: implications for receptor binding. , 2000 .
[87] L. Heinemann,et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. , 2005, Diabetes care.
[88] K. Geisen,et al. Biological activity in vivo of insulin analogues modified in the N-terminal region of the B-chain. , 1986, Biological chemistry Hoppe-Seyler.
[89] J. Patton,et al. (D) Routes of delivery: Case studies , 1992 .
[90] E. Canova‐Davis,et al. Semisynthesis of insulin: specific activation of the arginine carboxyl group of the B chain of desoctapeptide-(B23--30)-insulin (bovine). , 1981, Biochemistry.
[91] M. de Gasparo,et al. Synthesis and biological activity of seventeen analogues of human insulin. , 1979, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[92] B. Zinman,et al. Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes , 2005, Annals of Internal Medicine.
[93] S. Stoev,et al. Synthesis and properties of [A19-(p-fluorophenylalanine)] insulin. , 1988, Biological chemistry Hoppe-Seyler.
[94] Irving S. Johnson,et al. The trials and tribulations of producing the first genetically engineered drug , 2003, Nature Reviews Drug Discovery.
[95] T. Sanke,et al. Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin. , 1986, The Journal of clinical investigation.
[96] L. Illum,et al. Intranasal insulin delivery and therapy. , 1999, Advanced drug delivery reviews.
[97] Peter G Schultz,et al. Adding amino acids to the genetic repertoire. , 2005, Current opinion in chemical biology.
[98] P. Schultz,et al. Expanding the genetic code. , 2002, Chemical communications.
[99] Raul C Camacho,et al. Suppression of endogenous glucose production by mild hyperinsulinemia during exercise is determined predominantly by portal venous insulin. , 2004, Diabetes.
[100] G. Booker,et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. , 2004, Molecular endocrinology.
[101] P. Pilch,et al. Isolation of a proteolytically derived domain of the insulin receptor containing the major site of cross-linking/binding. , 1989, Biochemistry.
[102] F. Shojaee-Moradie,et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp , 2005, Diabetologia.
[103] R. Chance,et al. Research, Development, Production, and Safety of Biosynthetic Human Insulin , 1993, Diabetes Care.
[104] T. Forst,et al. Pulmonary insulin delivery by means of the Technosphere™ drug carrier mechanism , 2005, Expert opinion on drug delivery.
[105] A. Vaag,et al. Intranasal Administration of Insulin With Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects , 1992, Diabetic medicine : a journal of the British Diabetic Association.
[106] Š. Zórad,et al. Shortened insulin analogues: marked changes in biological activity resulting from replacement of TyrB26 and N-methylation of peptide bonds in the C-terminus of the B-chain. , 2004, Biochemistry.
[107] B. Zinman,et al. Hepatic Glucose Production Is Regulated Both by Direct Hepatic and Extrahepatic Effects of Insulin in Humans , 1996, Diabetes.
[108] H. Arnqvist,et al. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. , 2001, Diabetes care.
[109] H. Höcker,et al. Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine. , 1991, Biological chemistry Hoppe-Seyler.
[110] L. Slieker,et al. Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. , 1993, Advances in experimental medicine and biology.
[111] Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.
[112] T. Blundell,et al. Structure and evolution of insulins: Implications for receptor binding , 1992, BioEssays : news and reviews in molecular, cellular and developmental biology.
[113] M. Małecki. Genetics of type 2 diabetes mellitus. , 2005, Diabetes research and clinical practice.
[114] L. Sciacca,et al. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: Evidence for enhanced interactions with the insulin‐like growth factor‐I receptor , 1997, Molecular carcinogenesis.
[115] L. Vignati,et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.
[116] H S Tager,et al. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects. , 1986, The Journal of biological chemistry.
[117] Kun Huang,et al. Enhancing the activity of insulin at the receptor interface: crystal structure and photo-cross-linking of A8 analogues. , 2004, Biochemistry.
[118] B. Riniker,et al. Synthese von Humaninsulin. II. Aufbau des cyclischen Fragments A(1–13)†‡ , 1976 .
[119] J. Robinson,et al. Partially unfolded proteins efficiently penetrate cell membranes--implications for oral drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[120] E. Kojro,et al. Detection of a new hormone contact site within the insulin receptor ectodomain by the use of a novel photoreactive insulin. , 1992, The Journal of biological chemistry.
[121] M. Weiss,et al. How Insulin Binds: the B-Chain α-Helix Contacts the L1 β-Helix of the Insulin Receptor , 2004 .
[122] H S Tager,et al. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions. , 1992, Biochemistry.
[123] A. Riggs,et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[124] J. Reginster,et al. 1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN , 1987, The Lancet.
[125] Y. Okada,et al. Synthesis of two biologically active insulin analogues with modifications at the N-terminal and N- and C-terminal amino acid residues. , 1976, Biochemistry.
[126] P. Katsoyannis,et al. [12-asparagine-B] human insulin. An analogue with modification in the hydrophobic core of insulin. , 2009, International journal of peptide and protein research.
[127] Y. Kiso,et al. Total synthesis of human insulin by regioselective disulfide formation using the silyl chloride-sulfoxide method , 1993 .
[128] R. Mirmira,et al. Disposition of the phenylalanine B25 side chain during insulin-receptor and insulin-insulin interactions. , 1991, Biochemistry.
[129] H. Klein,et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. , 1996, The Biochemical journal.
[130] M. Weiss,et al. Chiral mutagenesis of insulin's hidden receptor-binding surface: structure of an allo-isoleucine(A2) analogue. , 2002, Journal of molecular biology.
[131] ENZYME-ASSISTED SEMISYNTHESIS OF HUMAN INSULIN , 1979 .
[132] J. Whittaker,et al. Structural biology of insulin and IGF1 receptors: implications for drug design , 2002, Nature Reviews Drug Discovery.
[133] D. Steiner,et al. A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[134] L. Thim,et al. Single chain des-(B30) insulin. Intramolecular crosslinking of insulin by trypsin catalyzed transpeptidation. , 2009, International journal of peptide and protein research.
[135] A. Fasano,et al. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. , 1997, The Journal of clinical investigation.
[136] E J Dodson,et al. X-ray analysis of the single chain B29-A1 peptide-linked insulin molecule. A completely inactive analogue. , 1991, Journal of molecular biology.
[137] Kenji. Suzuki,et al. Insulin Peptides. X. The Synthesis of the B-Chain of Insulin and Its Combination with Natural or Synthetis A-Chin to Generate Insulin Activity , 1964 .
[138] M. Spoden,et al. Structure-function relationships of des-(B26-B30)-insulin. , 2009, International journal of peptide and protein research.
[139] Claus Kristensen,et al. Alanine Scanning Mutagenesis of Insulin* , 1997, The Journal of Biological Chemistry.
[140] P. Katsoyannis,et al. A superactive insulin: [B10-aspartic acid]insulin(human). , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[141] M. A. Ruttenberg. Human Insulin: Facile Synthesis by Modification of Porcine Insulin , 1972, Science.
[142] M. Weiss,et al. Hierarchical protein folding: asymmetric unfolding of an insulin analogue lacking the A7-B7 interchain disulfide bridge. , 2001, Biochemistry.
[143] J. Eckel,et al. A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. , 2003, Diabetes.
[144] D. Howey,et al. Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial Experience , 1992, Diabetes Care.
[145] Donald E. Chickering,et al. Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.
[146] H. Tsuzuki,et al. Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin , 1979, Nature.
[147] Z. Dauter,et al. Structural origins of the functional divergence of human insulin-like growth factor-I and insulin. , 2002, Biochemistry.
[148] P. Katsoyannis,et al. The effect of modifications of the A5 and A19 amino acid residues on the biological activity of insulin. [Leu5-A] and [Phe19-A] sheep insulins , 1983 .
[149] R. B. Merrifield. Solid phase peptide synthesis. I. the synthesis of a tetrapeptide , 1963 .
[150] D R Owens,et al. Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.
[151] K. Bornfeldt,et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities , 1991, Diabetologia.
[152] P. Katsoyannis,et al. Chemical synthesis of [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] bovine insulins. , 2009, International journal of peptide and protein research.
[153] R. Geiger,et al. Austausch von A1-Glycin in Rinderinsulin gegen L- und D-Tryptophan , 1982 .
[154] B. Riniker,et al. Synthese von Humaninsulin. III. Aufbau des geschützten zweikettigen Fragments A(14‐21) ‐ B(17‐30) , 1976 .
[155] P. Katsoyannis,et al. Insulin Peptides. IX. The Synthesis of the A-Chain of Insulin and its Combination with Natural B-Chain to Generate Insulin Activity , 1963 .
[156] J. Rosenstock,et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. , 2001, Diabetes care.
[157] V. Ramesh,et al. 1H n.m.r. studies of insulin. Assignment of resonances and properties of tyrosine residues. , 1985, The Biochemical journal.
[158] K. Hermansen,et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. , 2001, Diabetes care.
[159] I. S. Johnson. Human insulin from recombinant DNA technology. , 1983, Science.
[160] T. Kjeldsen,et al. Yeast secretory expression of insulin precursors , 2000, Applied Microbiology and Biotechnology.
[161] G. Weitzel,et al. Further studies on the three-step-increase in activity due to the aromatic amino acids B24-26 (-Phe-Phe-Tyr-). , 1976, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[162] K. Geisen,et al. [(A1-D-alanine) insulin (author's transl)]. , 1975, Hoppe-Seyler´s Zeitschrift für physiologische Chemie.
[163] S. Gammeltoft. Insulin receptors: binding kinetics and structure-function relationship of insulin. , 1984, Physiological reviews.
[164] G. Bruno,et al. Sex Differences in Incidence of IDDM in Age-Group 15-29 yr: Higher risk in males in Province of Turin, Italy , 1993, Diabetes Care.
[165] R. Geiger,et al. [Bis (t-butyloxycarbonyl) insulin]. , 1971, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[166] K. Polonsky,et al. Insulin Wakayama: familial mutant insulin syndrome in Japan , 1987, Diabetologia.
[167] Zhan-Yun Guo,et al. Effects of Cysteine to Serine Substitutions in the Two Inter-Chain Disulfide Bonds of Insulin , 2001, Biological chemistry.
[168] J. Olefsky,et al. A structurally abnormal insulin causing human diabetes , 1979, Nature.
[169] D. Owens,et al. Inhaled human insulin , 2006, Nature Reviews Drug Discovery.
[170] A. Wollmer,et al. Shortened insulin with enhanced in vitro potency. , 1987, Biological chemistry Hoppe-Seyler.
[171] G. Slama,et al. Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross‐over study , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[172] R. Geiger,et al. Insulinanaloga durch Austausch von Al-Glycin gegen D-Aminosäuren und ω-Aminosäuren , 1980 .
[173] J. Eckel,et al. [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action. , 2003, Biochemical and biophysical research communications.
[174] L. Rosenfeld. Insulin: discovery and controversy. , 2002, Clinical chemistry.